- Home
- IPA vs NRSN Comparison
IPA vs NRSN Comparison
Compare IPA & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- NRSN
- Stock Information
- Founded
- IPA 1983
- NRSN 2017
- Country
- IPA Canada
- NRSN Israel
- Employees
- IPA N/A
- NRSN N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- NRSN Health Care
- Exchange
- IPA Nasdaq
- NRSN Nasdaq
- Market Cap
- IPA 19.3M
- NRSN 17.8M
- IPO Year
- IPA 2017
- NRSN 2021
- Fundamental
- Price
- IPA $0.41
- NRSN $1.12
- Analyst Decision
- IPA Strong Buy
- NRSN Hold
- Analyst Count
- IPA 2
- NRSN 1
- Target Price
- IPA $5.00
- NRSN N/A
- AVG Volume (30 Days)
- IPA 4.6M
- NRSN 129.6K
- Earning Date
- IPA 03-28-2025
- NRSN 04-04-2025
- Dividend Yield
- IPA N/A
- NRSN N/A
- EPS Growth
- IPA N/A
- NRSN N/A
- EPS
- IPA N/A
- NRSN N/A
- Revenue
- IPA $17,272,336.00
- NRSN N/A
- Revenue This Year
- IPA $1.88
- NRSN N/A
- Revenue Next Year
- IPA $9.90
- NRSN N/A
- P/E Ratio
- IPA N/A
- NRSN N/A
- Revenue Growth
- IPA 6.36
- NRSN N/A
- 52 Week Low
- IPA $0.27
- NRSN $0.51
- 52 Week High
- IPA $1.71
- NRSN $2.25
- Technical
- Relative Strength Index (RSI)
- IPA 49.79
- NRSN 51.47
- Support Level
- IPA $0.35
- NRSN $0.96
- Resistance Level
- IPA $0.41
- NRSN $1.17
- Average True Range (ATR)
- IPA 0.05
- NRSN 0.08
- MACD
- IPA 0.01
- NRSN 0.00
- Stochastic Oscillator
- IPA 61.93
- NRSN 66.24
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.